Previous 10 | Next 10 |
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of AL...
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects -- – In p53-mutant cancers, ALRN-6924 is designed to shield healthy cell...
3 High-Flying Penny Stocks To Watch In June 2020 There’s no question that penny stocks are some of the most volatile classes of stock out there. While it may look easy to trade penny stocks and make 10x your money, it takes a cool head and proven strategy to be consistent. The last ...
WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,071,149 shares at the public off...
Gainers: Vislink Technologies (NASDAQ: VISL ) +174% . More news on: Vislink Technologies, Inc., Cinedigm Corp., Kezar Life Sciences, Inc., Stocks on the move, , Read more ...
Aileron Therapeutics ( ALRN -16.8% ) prices an underwritten public offering of 9.1M shares at $1.10/share, for gross proceeds of $10M More news on: Aileron Therapeutics, Inc., Healthcare stocks news, , Read more ...
Aileron Therapeutics (NASDAQ: ALRN ) -21% on launch of equity offering. More news on: Aileron Therapeutics, Inc., Summit Wireless Technologies, Inc., Smartsheet Inc., Stocks on the move, , Read more ...
WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross proceeds of $10.0 million, before...
WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of t...
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN, Texas , July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first...
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...